Ministry of Health has authorized phase III studies of Neovasculgen

NexTgen has received approval from the Ministry of Health to conduct Phase III clinical trials of the gene therapy drug Neovasculgen® for the treatment of diabetic foot syndrome. Results of Phase I and II confirmed that the drug injection into the affected tissues reduces the healing time of ulcer defects and improves the quality of tissue regeneration. In Phase III research participation will include 188 patients from 5 clinical centers. It will last until March 2027.